Publication
Number of items: 21.
1 June 2015
  • In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile. (2015) D. Corbett, A. Wise, S. Birchall, P. Warn, Simon D. Baines, G. Crowther, J. Freeman, C. H. Chilton, J. Vernon, M. H. Wilcox and R. J. Vickers
    • 1 January 2015
  • SMT19969 as a treatment for Clostridium difficile infection : an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model. (2015) Simon D. Baines, G. S. Crowther, J. Freeman, S. Todhunter, R. Vickers and M. H. Wilcox
    • 30 April 2014
  • Comparison of planktonic and biofilm-associated communities of Clostridium difficile and indigenous gut microbiota in a triple-stage chemostat gut model. (2014) Grace S. Crowther, Caroline H. Chilton, Sharie L. Todhunter, Scott Nicholson, Jane Freeman, Simon D. Baines and Mark H. Wilcox
    • 14 October 2013
  • In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. (2013) C. H. Chilton, G. S. Crowther, Simon D. Baines, S. L. Todhunter, J. Freeman, H. H. Locher, A. Athanasiou and M. H. Wilcox
    • 2013
  • Evaluation of antimicrobial activity of ceftaroline against Clostridium difficile and propensity to induce C. difficile infection in an in vitro human gut model. (2013) Simon D. Baines, Caroline H. Chilton, Grace S. Crowther, Sharie L. Todhunter, Jane Freeman and Mark H. Wilcox
  • Mixed infection by Clostridium difficile in an in vitro model of the human gut. (2013) Simon D. Baines, Grace S. Crowther, Sharie L. Todhunter, Jane Freeman, Caroline H. Chilton, Warren N. Fawley and Mark H. Wilcox
  • Evaluation of the effect of oritavancin on Clostridium difficile spore germination, outgrowth and recovery. (2013) C. H. Chilton, J. Freeman, Simon D. Baines, G. S. Crowther, S. Nicholson and M. H. Wilcox
  • Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection. (2013) Grace S Crowther, Simon D. Baines, Sharie L Todhunter, Jane Freeman, Caroline H Chilton and Mark H Wilcox
    • 2011
  • Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model. (2011) Simon D. Baines, Alan R. Noel, Grace S. Huscroft, Sharie L. Todhunter, Rachael O'Connor, Joanne K. Hobbs, Jane Freeman, Andy M. Lovering and M. H. Wilcox
  • Nitazoxanide is active against Clostridium difficile strains with reduced susceptibility to metronidazole. (2011) Jane Freeman, Simon D. Baines, Sharie L. Todhunter, Grace S. Huscroft and M. H. Wilcox
    • 2009
  • Mecillinam : a low-risk antimicrobial agent for induction of Clostridium difficile infection in an in vitro human gut model. (2009) Simon D. Baines, Rachael O'Connor, Grace Huscroft, Katie Saxton, Jane Freeman and Mark H Wilcox
  • Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. (2009) Simon D. Baines, Rachel O'Connor, Katie Saxton, Jane Freeman and M. H. Wilcox
    • 2008
  • Emergence of reduced susceptibility to metronidazole in Clostridium difficile. (2008) Simon D. Baines, Rachael O'Connor, Jane Freeman, Warren N Fawley, Celine Harmanus, Paola Mastrantonio, Ed J. Kuijper and M. H. Wilcox
  • Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. (2008) Simon D. Baines, Rachael O'Connor, Katie Saxton, Jane Freeman and Mark H. Wilcox
  • In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin. (2008) Rachael O'Connor, Simon D. Baines, Jane Freeman and Mark H. Wilcox
    • 2007
  • Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. (2007) Jane Freeman, Simon D. Baines, Katie Saxton and Mark H. Wilcox
  • In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. (2007) T. Garnier, A. Mantyla, T. Jarvinen, J. Lawrence, Marc Brown and S.L. Croft
    • 2006
  • Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. (2006) Simon D. Baines, Katie Saxton, Jane Freeman and Mark H. Wilcox
    • November 2005
  • Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital. (2005) Jane Freeman, Joanna Stott, Simon D. Baines, Warren N. Fawley and Mark H. Wilcox
    • September 2005
  • Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. (2005) Jane Freeman, Simon D. Baines, Daniela Jabes and Mark H. Wilcox
    • June 2005
  • Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model. (2005) Simon D. Baines, Jane Freeman and Mark H. Wilcox